Every 8-K that Olaplex Holdings, Inc. (OLPX) has filed with the SEC in the last 24 months is listed below, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A 8-K covers material events a company has to report between its quarterly reports, so if you follow OLPX and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full OLPX filings page.
Olaplex Holdings, Inc. has completed its merger with Henkel US Operations Corporation, taking the company private. At the effective time of the merger, each outstanding share of Olaplex common stock (other than excluded and dissenting shares) was converted into the right to receive $2.06 in cash per share, and all such shares were cancelled.
The buyer valued Olaplex’s equity at approximately $1.4 billion and used cash on hand to fund the transaction. Olaplex also repaid about $357.6 million outstanding under its 2022 Credit Agreement, incurring no early termination penalties. Following the closing, Olaplex’s stock ceased trading on Nasdaq, the company is being delisted and deregistered, existing equity incentive plans were terminated, options and RSUs were cashed out or canceled per their terms, the board was reconstituted, and new charter and bylaws were adopted.
Olaplex Holdings, Inc. is moving toward resolving stockholder derivative litigation through a proposed settlement that has received preliminary court approval. The case involves derivative actions and a books-and-records demand related to issues similar to a prior securities class action against the company.
Under the proposed settlement, Olaplex will adopt specified corporate governance reforms and defendants’ insurers will pay $700,000 in attorneys’ fees and expenses, subject to court approval. The settlement, which would release all related derivative claims, is subject to final approval at a Settlement Hearing scheduled for July 27, 2026.
Olaplex Holdings reported first quarter 2026 results and reiterated its pending all-cash sale to Henkel for $2.06 per share, valuing the company at about $1.4 billion.
Net sales rose 2.5% to $99.4 million, driven by double-digit growth in Professional and Direct-to-Consumer channels, while Specialty Retail declined 13.3%. Net results swung to a net loss of $5.3 million from net income of $0.5 million, with diluted EPS at $(0.01). Adjusted EBITDA fell to $19.0 million with margin of 19.1%, down from 26.5%.
Olaplex ended the quarter with cash and cash equivalents of $326.2 million and long-term debt of $352.5 million. Given the Henkel transaction, the company will not host a conference call or provide updated financial guidance.
Olaplex Holdings, Inc. has agreed to be acquired by Henkel in an all-cash merger. Henkel will pay $2.06 per share, valuing Olaplex at approximately $1.4 billion, a premium of about 55% to the prior closing price and 45% to the 30-day VWAP.
Merger Sub will merge into Olaplex, which will become a wholly owned Henkel subsidiary and be delisted from Nasdaq. Advent-affiliated funds holding roughly 75% of shares approved the deal by written consent. Closing is subject to antitrust and other regulatory clearances and customary conditions, with an outside date that can extend to September 30, 2027. A $40.44 million termination fee may be payable by Olaplex to Henkel in specified scenarios.
Olaplex Holdings reported essentially flat fiscal 2025 net sales of $422.96 million, up 0.1%, but results weakened sharply. The company swung to a GAAP net loss of $9.25 million from net income of $19.52 million, while adjusted EBITDA fell to $93.87 million from $129.67 million, with margin down to 22.2% from 30.7%.
Fourth-quarter 2025 net sales rose 4.3% to $105.12 million, driven by 18.9% growth in Professional and 6.6% in Direct-to-Consumer, partly offset by a 14.5% decline in Specialty Retail. However, Q4 GAAP net loss widened to $13.10 million.
The balance sheet showed $318.73 million of cash and cash equivalents and $352.29 million of long-term debt as of December 31, 2025, reflecting substantial debt reduction over the year. For 2026, Olaplex guides net sales between $414 million and $435 million, with adjusted gross margin of 71%–72% and adjusted EBITDA margin of 21%–22%, slightly below 2025 levels.
Olaplex Holdings, Inc. (OLPX) furnished an 8‑K to announce its results of operations for the third quarter ended September 30, 2025. The company disclosed that a press release with these results was issued on November 6, 2025 and is included as Exhibit 99.1.
The information under Item 2.02 is expressly stated as “furnished,” not “filed,” under the Exchange Act, and is not incorporated by reference into other filings unless specifically referenced. The filing also lists the cover page interactive data as Exhibit 104.
Olaplex Holdings, Inc. reported a material event on Form 8-K disclosing a Stock Purchase Agreement dated August 20, 2025 among Olaplex, Inc., Purvala Bioscience, Inc., the stockholders and optionholders of Purvala, and Shareholder Representative Services LLC as representative of those holders. The filing also references a press release dated August 26, 2025 and includes the cover page interactive data file embedded in the Inline XBRL document. The Form 8-K is signed on behalf of Olaplex by Amanda Baldwin, Chief Executive Officer. The filing identifies a material transaction but provides no financial terms, closing conditions, or timing details within the provided excerpt.